Corcept Therapeutics
✓ VerifiedCortisol modulation for metabolic and oncologic disease
📊
$690M
Annual Revenue
👥
600
Employees
📦
5
Products
80%
80%
Profile Completeness
📄 About Corcept Therapeutics
Corcept Therapeutics develops Korlym (mifepristone) for Cushing syndrome and is advancing relacorilant for malignant hypercortisolism and other cortisol-dependent conditions.
🛡️
High Quality
Products
Products
🌐
Global
Distribution
Distribution
💡
Innovative
Technology
Technology
👥
Customer
Focused
Focused
📦 Featured Products
View All Products →
No products currently listed for Corcept Therapeutics.
📍 Location & Offices
View on Map
🗺️
Menlo Park, USA
📋 Request a Quote
Send your requirements directly to Corcept Therapeutics. Response typically within 48 hours.
